Chapter-8

References

REFERENCES:1. Chien YW, 1992,. Novel drug delivery systems, 2nd Edition; Marcel Dekker Inc: New York, 139-40. 2. Wani M., 2008, Controlled Released System A Review,

Pharmainfo.net , Vol. 6, Issue 1,. 3. Hui HW, Robinson JR, Lee VHL. Design and fabrication of oral controlled release drug delivery systems. In: Robinson JR, Lee V, editors. Controlled drug delivery fundamentals and applications. 2nd Ed.; Marcel Dekker: New York: Inc; p. 373-4. 4. Jantzen GM, Robinson JR, 1996, Sustained- and controlled-release drug delivery systems. In: Banker GS, Rhodes CT, editors. Modern pharmaceutics. 3rd Ed.; Marcel Dekker Inc; New York; 575-609. Gudsoorkar VR, Rambhau D., 1993, Extended release of drugs. The Eastern Pharmacist, 36(429); 17-22. 5. Lachman L, Lieberman HA, Kanig JL., 1987, The theory and practice of industrial pharmacy, 3rd Ed.; Varghese Publishing House Bombay, 293345,430. 6. Remington: The science and Practice of Pharmacy., 19th Ed.; 1660, 1676, 1995. 7. Robinson J. R. Lee L. H., 1987, Controlled Drug Delivery: Fundamentals and Applications, 2nd Ed. 29, 312-319. 8. Alderman D. A., 1984, International Journal of Pharmaceutical Technology and Product Manufacture. , 1(5). 9. M Flu Lu et al, 1991, Drug Dev. Ind. Pharm, 17(4), 1987-2004,. 10. Nigayale A. G. et al. , 1990, Drug Dev. Ind. Pharm 16, 2-8. 11. Pandey V., Manavalan R., Rajan T. et al, 2003, Formulation and release characteristics of Extended release diltiazem hydrochloride tablet, Indian Journal of Pharmaceutical Science , 65(1):44-8. 12. Hoffman A., 1998, Pharmacodynamic aspects of Extended release preparations, Adv Drug Del Rev, 33: 185-99. 13. Jain NK, 2002, Controlled and novel drug delivery, 1 st Ed.; CBS Publishers; New Delhi Page 80

NIMS Institute of Pharmacy, NIMS University Jaipur

Chapter-8

References

14. Yie W, Chien, 2005, Rate controlled drug delivery systems. 2nd Ed. Marcel Dekker; New York, Revised and expanded,. 15. Jose G., Hossein O, Khalid S, 2003, Progress in gastroretentive drug delivery systems. Solid dose research and development, Pharmatech, 15256. 16. Jaber E, Naser D, 2004, Formulation of sustrained release lithium carbonate matrix tablets: influence of hydrophilic materials on the release rate and in vitro in vivo evaluation, Journal Pharmaceutical Science, 7: 338-44. 17. Aditya ST, Ketan AM, Larry LA, Stephen WH, 2004, Influence of methacrylic and acrylic acid polymers on the release performance of weakly basic drugs from Extended release hydrophilic matrix, Journal Pharmaceutical Science.,93,2319-31. 18. Chowhan ZT. Role of binders in moisture-induced hardness increase in compressed tablets and its effect on in vitro disintegration and dissolution. J Pharm Sci 1980; 69: 14. 19. Rowe RC. The adhesion of film coatings to tablet surfaces the effect of some direct compression excipients and lubricants. J Pharm Pharmacol 1977; 29: 723726. 20. Rowe RC. The molecular weight and molecular weight distribution of hydroxypropyl methylcellulose used in the film coating of tablets. J Pharm Pharmacol 1980; 32: 116119. 21. Banker G, Peck G, Jan S, Pirakitikulr P. Evaluation of hydroxypropyl cellulose and hydroxypropyl methyl cellulose as aqueous based film coatings. Drug Dev Ind Pharm 1981; 7: 693716. 22. Okhamafe AO, York P. Moisture permeation mechanism of some aqueousbased film coats. J Pharm Pharmacol 1982; 34 (Suppl.): 53P. 23. Alderman DA, Schulz GJ. Method of making a granular, cold water dispersible coating composition for tablets. United States Patent No. 4,816,298; 1989. 24. Patell MK. Taste masking pharmaceutical agents. United States Patent No. 4,916,161; 1990.

NIMS Institute of Pharmacy, NIMS University Jaipur

Page 81

Chapter-8

References

25. Hardy JG, Kennerley JW, Taylor MJ, et al. Release rates from sustainedrelease buccal tablets in man. J Pharm Pharmacol 1982; 34 (Suppl.): 91P. 26. Hogan JE. Hydroxypropylmethylcellulose sustained release technology. Drug Dev Ind Pharm 1989; 15: 975999. 27. Shah AC, Britten NJ, Olanoff LS, Badalamenti JN. Gel-matrix systems exhibiting bimodal controlled release for oral delivery. J Control Release 1989; 9: 169175. 28. Wilson HC, Cuff GW. Sustained release of isomazole from matrix tablets administered to dogs. J Pharm Sci 1989; 78: 582584. 29. Dahl TC, Calderwood T, Bormeth A, et al. Influence of physicochemical properties of hydroxypropyl methylcellulose on naproxen release from sustained release matrix tablets. J Control Release 1990; 14: 110. 30. Banker G, Peck G, Williams E, et al. Microbiological considerations of polymer solutions used in aqueous film coating. Drug Dev Ind Pharm 1982; 8: 4151. 31. Anonymous. Final report on the safety assessment of

hydroxyethylcellulose,

hydroxypropylcellulose,

methylcellulose,

hydroxypropyl methylcellulose and cellulose gum. J Am Coll Toxicol 1986; 5(3): 160. 32. FAO/WHO. Evaluation of certain food additives and contaminants. Thirtyfifth report of the joint FAO/WHO expert committee on food additives. World Health Organ Tech Rep Ser 1990; No. 789. 33. Lewis RJ, ed. Saxs Dangerous Properties of Industrial Materials, 11th edn. New York: Wiley, 2004: 2054. 34. UCB (2007-11-29). "UCB Announces FDA Filing for drug-x in the Treatment of Diabetic Neuropathic Pain". Press release. Retrieved 200711-29 35. National Society for Epilepsy. Epilepsy: Information on epileptic seizures.Available at:http://www.epilepsynse.org.uk/PAGES/whatsnew/pr/ep_facts.cfm [Accessed 15 August 2008].

NIMS Institute of Pharmacy, NIMS University Jaipur

Page 82

Chapter-8

References

36. Ben-Menachem, E. Lacosamide: an investigational drug for adjunctive treatment of partial-onset seizures. Drugs of Today 2007; 43 Available at: www.prous.com/journals 37. http://www.ncbi.nlm.nih.gov/pubmedhealth/PMH0000506/ 38. Gupta s., Kapoor V., Kapoor B., Itopride: A Novel Prokinetic agent; JK Science A Drug Review; 2004; 6(2); 106-108. 39. Mcquaid KR., Dyspepsia. In: Mark Feldman et al (eds.), Sleisenger & Fordtran's Gastrointestinal and Liver Disease

Pathophysiology/Diagnosis/Management.7th edition 2002; 1; 102-18. 40. Pasricha PJ., Prokinetic agents, antiemetics agents used in irritable bowel syndrome. In: Hardman JG et al (eds.), Goodman and Gilman'ss The Pharmacological Basis of Therapeutics, 10th edition, New York, McGraw Hill Book Inc.; 2001; 1021. 41. Wysowski DK., Corken A., Gallo TH et al. Post-marketing reports of QT prolongation & ventricular arrhythmias in association with cisapride and food and Drug administration regulatory actions; American Journal of Gastroenterology; 2001; 96; 1698-1703. 42. Mushiroda T., Douya R., Takahara E., Nagata O., The involvement of flavin containing monooxygenase but not CYP3A4 in metabolism of itopride hydrochloride, a gastrokinetic agent: comparison with cisapride and Mosapride citrate. Drug Metab Dispos 2000; 28: 1231-37. 43. Gupta s., Kapoor V., Kapoor B., Itopride: A Novel Prokinetic agent; JK Science A Drug Review; 2004; 6(2); 106-108. 44. Mcquaid KR., Dyspepsia. In: Mark Feldman et al (eds.), Sleisenger & Fordtran's Gastrointestinal and Liver Disease

Pathophysiology/Diagnosis/Management.7th edition 2002; 1; 102-18. 45. Pasricha PJ., Prokinetic agents, antiemetics agents used in irritable bowel syndrome. In: Hardman JG et al (eds.), Goodman and Gilman'ss The Pharmacological Basis of Therapeutics, 10th edition, New York, McGraw Hill Book Inc.; 2001; 1021. 46. Wysowski DK., Corken A., Gallo TH et al. Post-marketing reports of QT prolongation & ventricular arrhythmias in association with cisapride and

NIMS Institute of Pharmacy, NIMS University Jaipur

Page 83

Chapter-8

References

food and Drug administration regulatory actions; American Journal of Gastroenterology; 2001; 96; 1698-1703. 47. Mushiroda T., Douya R., Takahara E., Nagata O., The involvement of flavin containing monooxygenase but not CYP3A4 in metabolism of itopride hydrochloride, a gastrokinetic agent: comparison with cisapride and Mosapride citrate. Drug Metab Dispos 2000; 28: 1231-37. 48. http://www.symedlabs.com/p6.htm 49. Kibbe AH., Handbook of pharmaceutical excipients; American

Pharmaceutical Association and Pharmaceutical Press, Washington London; 2000; 3rd Ed; 102-106. 50. Lachman L., Lieberman HA., Kanig JL., The theory and practice of Industrial pharmacy, Varghese Publishing House Bombay; 1987; 171-293. 51. Aulton ME., The Science of dosage form design; Churchill living stone; 2002; 2nd edition; 414-418. 52. Cooper J, Gun C, Powder Flow and Compaction. Inc Carter SJ, Eds. Tutorial Pharmacy. New Delhi, hidix CBS Publishers and Distributors; 1986:211-233. 53. Martin A, Micromeretics, In: Martin A, ed. Physical Pharmacy.Baltimores, MD: Lippincott Williams and Wilkins; 2001:423-454. 54. ICH topic 8 Pharmaceutical guidelines, Note for Guidance on Pharmaceutical Developments, (EMEA/CHMP167068/2004). 55. Baertschi, S. W., Pharmaceutical stress testing, predicting drug degradation, Taylor and Francis group, 2005, 344-350. 56. The Indian Pharmacopoeia; Ministry of Health and Family Welfare, Government of India, Controller of Publications, New Delhi; 1996; 4th Edition; Volume II. 57. Moore JW., Flanner HH., Mathematical comparison of curves with an emphasis on in-vitro dissolution profiles; Pharmaceutical Technology; 1996; 20(6); 64-74. 58. Paulo C., Jose Manuel, Sousa L., Modeling and comparison of dissolution profiles; European Journal of Pharmaceutical Science; 2001; 13; 123-133.

NIMS Institute of Pharmacy, NIMS University Jaipur

Page 84

Chapter-8

References

59. Korsmeyer RW., Peppas NA., Effect of the morphology of hydrophilic polymeric matrices on the diffusion and release of water soluble drugs, Journal of Membr. Science; 1981; 9; 211227. 60. Higuchi T., Mechanism of sustained action medication, Theoretical analysis of rate release of solid drugs dispersed in solid matrices; Journal of Pharmaceutical Science; 1963; 52; 1145-1149. 61. ICH GUIDELINES Q1A (R2), Guidance for industry, stability testing of new drug substance and products (Available on: http://

http://www.ich.org).

NIMS Institute of Pharmacy, NIMS University Jaipur

Page 85